

THIS AGREEMENT, effective from the March, 1st, 2014, is made between **Medipan / GA Generic Assays GmbH** (hereinafter called "**Medipan**") AND *Forum per la Ricerca sulle Malattie Autoimmuni* (hereinafter called "**FIRMA**").

Background

- Medipan evaluated the automated interpretation system AKLIDES with blinded sera provided by the FIRMA group regarding the detection of antinuclear antibodies (ANA);
- this evaluation was part of a comparative study of the FIRMA group to gauge the usability of automated interpretation of indirect immunofluorescence (IIF) of ANA patterns;
- results from the study have already sent to FIRMA for data analysis
- Medipan is developing a test for the detection of ANA antibodies using new coupling technologies.

Then,

after having conducted the evaluation, Medipan would like to employ the same blinded sera for the evaluation of a novel IIF assay format combining screening and confirmatory ANA testing (CytoBead technology).

The antibodies aid in the clinical diagnosis of connective tissue diseases and Medipan wishes to engage the FIRMA to give advice on the evaluation of diagnostic value of the new test as well as technical considerations.

Prof. Dr. Dirk Roggenbuck
General Manager / Geschäftsführer
Medipan / GA Generic Assays GmbH
L.-Erhard-Ring 3
15827 Dahlewitz/Berlin - Germany

Prof. PierLuigi Meroni
FIRMA President
Professor of Rheumatology , University of Milan
Head Dept. Rheumatology
Ist. Gaetano Pini, Milan - Italy